Serum sFlt-1/PlGF ratio combined with ANXA2 correlates with adverse pregnancy outcomes in women with suspected preeclampsia

An sFlt-1/PlGF ratio ≥ 85 combined with circulating ANXA2 < 6.13 ng/mL accurately identifies those at high risk for PE-related adverse outcomes, and its early warning efficacy is significantly superior to current single-biomarker strategies. This model provides a quantitative tool based on placental pathology for the timing of intervention in pregnant women with suspected PE and has potential for clinical translation.